NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Johnson & Johnson (NYSE:JNJ) said it has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder cancer, or MIBC, due to disappointing data. The drugmaker had ...

Bill Russell and Jim Rieker are survivors. Both diagnosed with bladder cancer, the men have made it their mission to help others with the disease through the Bladder Cancer Advocacy Network, the ...

The FDA approved Imfinzi with chemotherapy for neoadjuvant treatment in muscle invasive bladder cancer, followed by adjuvant Imfinzi post-cystectomy. The phase 3 NIAGARA trial demonstrated significant ...